Prospective Observational Study of Disease Progression in Chronic Hepatitis C
Active, not recruiting
- Conditions
- Hepatitis C, ChronicDisease ProgressionLiver Cirrhosis
- Registration Number
- NCT02011932
- Lead Sponsor
- Beijing YouAn Hospital
- Brief Summary
The purpose of this study is to determine the progression of chronic hepatitis C patients infected by paid plasma donation,and explore the possible pathogenic mechanisms of disease progression in chronic hepatitis C.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 133
Inclusion Criteria
- All these patients had a definite history of regular plasma donations with repeated blood cell re-transfusions.
- The Hepatitis C Virus antibody was positive.
- All patients did not receive interferon therapy before being recruited.
Exclusion Criteria
- Patients with evidences for other forms of liver diseases.
- The coinfection with hepatitis B virus or other virus.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Fibrosis progression rate 20 years The incidence of cirrhosis 20 years Risk factors for the occurrence of cirrhosis 20 years
- Secondary Outcome Measures
Name Time Method Number of participants with chronic hepatitis C-related complications 20 years The incidence of hepatocellular carcinoma 20 years
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms drive disease progression in chronic hepatitis C patients infected via plasma donation?
How does the progression of chronic hepatitis C in plasma donation-infected patients compare to other transmission routes in terms of treatment outcomes and response to direct-acting antivirals (DAAs)?
Which biomarkers are associated with accelerated fibrosis or cirrhosis development in NCT02011932 chronic hepatitis C cohort?
What are the long-term adverse events observed in chronic hepatitis C patients from plasma donation-related infections and how are they managed clinically?
What combination therapies or novel drug targets have emerged for chronic hepatitis C management since the initiation of the Beijing YouAn Hospital observational study NCT02011932?